New drug combination with radiation for advanced soft tissue sarcoma
Part of Cancer clinical trials.
This trial is testing a new combination of four treatments (an experimental drug, two chemo-like drugs, and radiation) for advanced soft tissue sarcoma that hasn't responded to earlier treatments. The goal is to see if this combination can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 14 to 75 years old.
- You must have advanced soft tissue sarcoma (a type of cancer in the body's soft tissues, like muscle, fat, or blood vessels).
- Your sarcoma must have gotten worse after at least one prior treatment (like chemotherapy).
- You should be in fairly good overall health – able to do most daily activities without needing to rest in bed for more than half the day.
- Your liver, kidneys, and blood counts must be within certain limits, and you must not have serious heart or breathing problems, or active hepatitis B or C, or HIV.
- You must not have had certain other sarcoma types like Ewing sarcoma, rhabdomyosarcoma, or GIST.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HS-20093, combined with other treatments for people with advanced bone or soft tissue sarcoma. The goal is to see if these combinations can shrink tumors or slow their growth.
This trial tests a combination of radiation therapy and two drugs (anlotinib and penpulimab) given before surgery for soft tissue sarcoma. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new way of giving radiation therapy (called spatially fractionated radiotherapy) combined with a treatment strategy called PraG (pembrolizumab and granulocyte-macrophage colony-stimulating factor) for people with soft tissue sarcoma that cannot be removed or has spread. The goal is to see if the combination can help shrink or control the cancer.
This trial tests a new drug called bexmarilimab combined with doxorubicin for people with soft-tissue sarcoma that has spread to other parts of the body. The goal is to see if the combination is safe and works better than doxorubicin alone.
This trial tests a new combination therapy: an injected virus (OVV-01) alongside an immunotherapy drug (AK112) for people with advanced soft tissue sarcoma that hasn't responded to usual treatments. The aim is to see if this approach can help shrink tumors or slow their growth.
This study tests a combination of two drugs (anlotinib and bempegaldesleukin) plus standard chemotherapy and radiation for people with advanced soft tissue sarcoma that has spread or can't be removed. The goal is to see if this combination helps shrink tumors and control the cancer.
Hear when a new Soft Tissue Sarcoma (STS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.